| Autor: |
Philipp Gauckler, Jana S. Kesenheimer, Duvuru Geetha, Balazs Odler, Kathrin Eller, Timothee Laboux, Federico Alberici, Mattia Zappa, Natasha Chebotareva, Sergey Moiseev, Marco Bonilla, Kenar D. Jhaveri, Julie Oniszczuk, Vincent Audard, Denise Costa, Gianna Mastroianni-Kirsztajn, Annette Bruchfeld, Masahiro Muto, Martin Windpessl, Gert Mayer, Andreas Kronbichler |
| Jazyk: |
angličtina |
| Rok vydání: |
2023 |
| Předmět: |
|
| Zdroj: |
Frontiers in Immunology, Vol 14 (2023) |
| Druh dokumentu: |
article |
| ISSN: |
1664-3224 |
| DOI: |
10.3389/fimmu.2023.1228457 |
| Popis: |
IntroductionPatients with immune-mediated glomerular diseases are considered at high risk for severe COVID-19 outcomes. However, conclusive evidence for this patient population is scarce.MethodsWe created a global registry and retrospectively collected clinical data of patients with COVID-19 and a previously diagnosed immune-mediated glomerular disease to characterize specific risk factors for severe COVID-19 outcomes.ResultsFifty-nine patients with a history of immune-mediated glomerular diseases were diagnosed with COVID-19 between 01.03.2020 and 31.08.2021. Over a mean follow-up period of 24.79 ± 18.89 days, ten patients (16.9%) developed acute kidney injury. Overall, 44.1% of patients were managed in an outpatient setting and therefore considered as having “non-severe” COVID-19, while 55.9% of patients had severe COVID-19 requiring hospitalization including worse outcomes. Comparing both groups, patients with severe COVID-19 were significantly older (53.55 ± 17.91 versus 39.77 ± 14.95 years, p = .003), had lower serum albumin levels at presentation (3.00 ± 0.80 g/dL versus 3.99 ± 0.68 g/dL, p = .016) and had a higher risk of developing acute kidney injury (27% versus 4%, p = .018). Male sex (p |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
